Trial redux with continued compassionate use is the best you can hope for.
Between her letter to the FDA and filing disclosure re endpoints, Powers must feel she given her shareholders enough of a warning. It's Smith, Bigger and Lappin who keep expecting more / playing the stock and retail.
Makes me wonder if Powers already has financiers commitment for another Plll??
With Cognate and now Advent up and running why does LL want to expand UCLA's manufacturing capacity?
Reverse split or reverse merge or both. Definitely needs new management to continue, IMO.
News 
Market Data 
Discover 
AI
